Pancreatic CSCs were first reported by the laboratory of Diane M. Simeone [20], showing that a CD44+CD24+EpCAM+ (epithelial cell adhesion molecule)/ESA+ (epithelial specific antigen) subpopulation, accounting for 0.2–0.8% of pancreatic cancer cells from primary human tumors, was able to display stem cell features of self-renewal, generate differentiated progeny and exhibited a high potential to form tumors in immunocompromised mice (approximately 100-fold increased tumorigenic potential as compared to non-triple-positive cancer cells). This evidence concerns the gene CD44 and cancer.